Phio Pharmaceuticals Net Income Over Time
| PHIO Stock | USD 0.92 0.06 6.98% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Phio Pharmaceuticals Performance and Phio Pharmaceuticals Correlation. Will Biotechnology sector continue expanding? Could Phio diversify its offerings? Factors like these will boost the valuation of Phio Pharmaceuticals. Anticipated expansion of Phio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Phio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Phio Pharmaceuticals Corp's market price often diverges from its book value, the accounting figure shown on Phio's balance sheet. Smart investors calculate Phio Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Phio Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Phio Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phio Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Phio Pharmaceuticals Corp and related stocks such as Transcode Therapeutics, Kiora Pharmaceuticals, and In8bio Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNAZ | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (607.2 K) | (2.3 M) | (6.8 M) | (17.6 M) | (18.5 M) | (16.8 M) | (15.1 M) | (14.3 M) |
| KPRX | (6 M) | (6 M) | (6 M) | (3.9 M) | (1.8 M) | (8.4 M) | (13.3 M) | (13.2 M) | (10.8 M) | (7.1 M) | (6.9 M) | (13.8 M) | (13.6 M) | (12.5 M) | 3.6 M | 3.2 M | 3.4 M |
| INAB | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (5.1 M) | (8.6 M) | (14.7 M) | (27.4 M) | (30 M) | (30.4 M) | (27.4 M) | (26 M) |
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (6.8 M) |
| APRE | (3.5 M) | (254 K) | (254 K) | (436.2 K) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.5 M) | (28.1 M) | (53.9 M) | (36.5 M) | (112.7 M) | (14.3 M) | (13 M) | (11.7 M) | (12.2 M) |
| MRKR | (1.1 M) | (2 M) | (5.9 M) | (5.5 M) | (30.9 M) | (34.1 M) | (2.5 M) | (11 M) | (148 M) | (21.4 M) | (28.7 M) | (41.9 M) | (29.9 M) | (8.2 M) | (10.7 M) | (9.7 M) | (10.1 M) |
| GLTO | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (38.4 M) | (34.8 M) | (51.8 M) | (61.6 M) | (38.3 M) | (21.4 M) | (19.3 M) | (20.3 M) |
| CELZ | 1.4 K | (24.1 K) | (25.6 K) | (27.3 K) | (28 K) | (30.8 K) | (766.1 K) | (2.7 M) | (13.7 M) | (8.5 M) | (36.3 M) | 19.2 M | (10.1 M) | (5.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.7 M) | (12.1 M) | (14.6 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| APVO | (53.3 M) | (53.3 M) | (53.3 M) | (53.3 M) | (51.1 M) | (59.3 M) | (112.4 M) | 7 M | (53.7 M) | (44.7 M) | (17.8 M) | (27.3 M) | 8 M | (17.4 M) | (24.1 M) | (27.7 M) | (29.1 M) |
Phio Pharmaceuticals Corp and related stocks such as Transcode Therapeutics, Kiora Pharmaceuticals, and In8bio Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Phio Pharmaceuticals Corp financial statement analysis. It represents the amount of money remaining after all of Phio Pharmaceuticals Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Phio Pharmaceuticals Corp | PHIO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 11 Apex Drive, |
| Exchange | NASDAQ Exchange |
USD 0.92
Check out Phio Pharmaceuticals Performance and Phio Pharmaceuticals Correlation. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Phio Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.